Back to programme
Tue 21 Oct 25 14:00-15:30
SCS
Pharmaceutical and non pharmaceutical intervention SCS07
Auditorium 1 - Plenary Hall
Chairs
Peter OPENSHAW
ESWI Board Member, Imperial College
Read more
Nisreen OKBA
Icahn School of Medicine at Mount Sinai, United States
Read more
Ended Now live Upcoming
  1. Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States
    Alicia STEINCSL Seqirus, Australia
  2. Effectiveness of 2024/25 COVID-19 vaccines against symptomatic SARS-CoV-2 infection in the target group for vaccination, European VEBIS primary care multicentre study, autumn/winter 2024/25
    To be confirmed
  3. Differential protection of prior infection and repeated vaccination against SARS-CoV-2 infection in Omicron BA.2 to JN.1 predominance: a prospective cohort study
    Nicole Ngai Yung TSANGThe University of Hong Kong, Hong Kong SAR China
  4. Vaccine effectiveness against medically attended influenza at primary care level in the paediatric population, 2024/25 season, Europe
    Héloïse LUCACCIONIEpiconcept, France
  5. IMMUNOGENICITY AND SAFETY OF HIGH DOSE FORMULATIONS OF MF59-ADJUVANTED CELL-DERIVED INFLUENZA VACCINE IN ADULTS AGED 50 YEARS AND OLDER: TWO PHASE 2 RANDOMISED CONTROLLED TRIALS
    Frank ALBANOCSL Seqirus, Australia